Sugi Predict

Sugi Predict / Compounds / SCHEMBL910888

SCHEMBL910888

SCHEMBL910888

COc1ccccc1CCC=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 2/20 0.58
▸ CHRM1 P11229 2/20 0.58
▸ CHRM3 P20309 1/20 0.58
▸ TAAR1 Q96RJ0 1/20 0.58
▸ IDO1 P14902 2/20 0.53
▸ SIGMAR1 Q99720 1/20 0.51
▸ AOC3 Q16853 1/20 0.51
▸ MTNR1A P48039 1/20 0.51
▸ MTNR1B P49286 1/20 0.51
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ MPO P05164 2/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ ABCB1 P08183 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9694624 0.89 CHRM2 (0.55) CHRM2CHRM1CHRM3TAAR1SIGMAR1
SCHEMBL5045738 0.86 CHRM2 (0.45) CHRM2CHRM1CHRM3TAAR1IDO1
SCHEMBL7333236 0.84 CA12 (0.54) CA12CA1CA2CA14ALDH1A1
SCHEMBL8507656 0.82 TAAR1 (0.60) CHRM2CHRM1CHRM3TAAR1IDO1
SCHEMBL910556 0.81 L3MBTL1 (0.56) CHRM2CHRM1CHRM3ALDH1A1
SCHEMBL28858018 0.81 TAAR1 (0.75) CHRM2CHRM1CHRM3TAAR1IDO1
SCHEMBL6157014 0.81 TAAR1 (0.58) CHRM2CHRM1CHRM3TAAR1IDO1
SCHEMBL30136331 0.81 TAAR1 (0.58) CHRM2CHRM1CHRM3TAAR1IDO1
SCHEMBL8062343 0.81 TAAR1 (0.58) CHRM2CHRM1CHRM3TAAR1IDO1
SCHEMBL2470010 0.80 MTNR1A (0.59) CHRM2CHRM1CHRM3TAAR1MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2277599-B1 Reductive colour removal HENKEL AG & CO KGAA (DE) 2019-01-23 — — EP claimed
EP-2277599-A1 Reductive colour removal Henkel AG & Co. KGaA (DE) 2011-01-26 — — EP claimed
EP-1996145-A2 REDUCTIVE COLOUR REMOVAL Henkel AG & Co. KGaA (DE) 2008-12-03 — — EP claimed
WO-2007107310-A2 REDUCTIVE COLOUR REMOVAL HENKEL AG & CO. KGAA (DE) 2007-09-27 — — WO claimed
US-6388081-B1 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries LION BIOSCIENCE AG (DE) 2002-05-14 — — US claimed
US-6262269-B1 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries TREGA BIOSCIENCES, INC. 2001-07-17 — — US claimed
EP-0983507-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 2000-03-08 — — EP claimed
EP-0977989-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2000-02-09 — — EP claimed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 — — WO claimed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 — — WO claimed
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS INC (US) 2025-10-16 — — US disclosed
CN-119707776-A Indole compound, pharmaceutical composition, preparation method and application thereof 山东绿叶制药有限公司 2025-03-28 — — CN disclosed
CN-119698412-A 5-HT2A receptor agonist, and preparation method and application thereof 上海翊石医药科技有限公司 2025-03-25 — — CN disclosed
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 — — WO disclosed
EP-2277597-B2 Reductive colour removal HENKEL AG & CO KGAA (DE) 2024-06-26 — — EP disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 — — EP disclosed
CN-1049660-A Aminoketone derivative and application thereof MITZUI TOATSU CHEMICALS INC (JP) 1991-03-06 — — CN disclosed
WO-1989008650-A1 THIAZOLIDINEDIONE HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1989-09-21 — — WO disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 — — US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 CHRM2 2577/4885CHRM1 2424/4885CHRM3 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.